Oculis (OCS) stock jumps as the FDA grants Breakthrough Therapy designation for its eye disease drug Privosegtor targeted at optic neuritis. Read more here.

Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received U.S. FDA Breakthrough Therapy designation for optic neuritis, supported by positive Phase 2 ACUITY data and ...

His devastating diagnosis came after a routine eye examination and subsequent investigations.

Oculis Holding AG (OCS) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 4:30 PM ESTCompany ParticipantsRiad Sherif - CEO ...

Oculis Holding (OCS) is back in focus after the U.S. FDA granted breakthrough therapy designation to its neuroprotective candidate Privosegtor for optic neuritis, supported by positive Phase 2 ACUITY ...

For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging advances, from gene editing and stem cells to microchips and laser-based ...

This roundup highlights recent FDA updates related to drug approvals and devices used by optometric eye care professionals.

Eye disease specialist Oculis SA is laying plans to branch out into multiple sclerosis (MS) after the phase II trials of its acute optic neuritis (AON) drug, privosegtor, showed it reduced levels of ...

FDA alerts and updates on the latest drug and device approvals, recalls, and other regulatory developments in ophthalmology.

Detailed price information for Garrett Motion Inc (GTX-Q) from The Globe and Mail including charting and trades.

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...